CapsoVision, Inc (CV) company profile

CVNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30383% above fair value

$6.03−0.24 (-3.83%)

Close on Nov 13, 2026Market cap $301.78MP/E –Yield –

About CapsoVision

Electromedical & Electrotherapeutic Apparatus, SIC 3845

The company is a medical technology firm that develops diagnostic and screening products for identifying abnormalities in the gastrointestinal tract. Its principal commercial offering is the CapsoCam capsule endoscopy system, which includes the CapsoCam Plus single-use capsule that captures panoramic images with onboard storage, along with viewing software platforms known as CapsoCloud and CapsoView. The company is also developing the CapsoCam Colon capsule and auxiliary products such as a delivery device and a patency capsule. Its primary customers are gastroenterologists practicing in clinics and hospital settings.

Corporate headquarters are located in Saratoga, California. The company distributes its products domestically in the United States through a direct sales team, while serving international markets through internal sales personnel and independent distributors. Across its clinical and commercial operations, its small-bowel endoscopy capsule has been administered to more than 161,000 patients, and the business maintains an intellectual property portfolio consisting of more than 140 issued patents.

Summary of the business section of CapsoVision's latest annual report, written by StockData.

Company profile

Company

Legal name: CapsoVision, Inc
Founded: 2005
Headquarters: Saratoga, CA
Address: 18805 Cox Avenue Suite 250 95070
Phone: (408) 370-4790
Website: capsovision.com
Employees: 99, Dec 31, 2025
Industry: Electromedical & Electrotherapeutic Apparatus
Incorporated in: Delaware
Fiscal year ends: December 31
Auditor: Baker Tilly US, LLP, Santa Clara, California

Stock & identifiers

Ticker: CV
Exchange: Nasdaq
IPO date: Jul 3, 2025
Shares outstanding: 50M, Aug 12, 2026
Filer category: <br>Emerging growth company
SEC CIK: 1378325
CUSIP: 140935107
ISIN: US1409351079
FIGI: BBG00KHZ9QJ2
Share class FIGI: BBG00KHZ9QK0
LEI: 529900I9VO18RX33ME31
EIN: 20-3369494

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

Name	Position	Shares owned
Kang-Huai Wang	See Remarks, Director	721,732
Douglas Patrick Atkinson	Head of Global Sales	107,357
David Michael Garcia	Sr. VP of Finance	–
Rebecca Ann Petersen	Director of Clinical Affairs	24,834
Kevin Michael Lundquist	Chief Financial Officer	–
David Stanley Shields	Director	0
Joanne Carol Imperial	Director	1,687
Hui Ying Kuo	Director	15,263
Julia S. Gouw	Director	4,909
Wen-Herng Henry King	Director	25,619
Michele Harari	Director	61,065
Chen Lung Tsai	Director	120,385

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

Executive	Salary	Bonus	Option awards	Other	Total	vs. prior year
Kang-Huai (Johnny) Wang President and Chief Executive Officer	$250.00K	–	–	–	$250.00K	-19%
David Garcia Senior Vice President, Finance (3)	$50.00K	$12.50K	$562.78K	–	$625.28K	–
Douglas Atkinson Senior Vice President of Global Sales (4)	$283.15K	$134.39K	–	–	$417.54K	-1%
Kevin Lundquist Former Chief Financial Officer (5)	$213.13K	–	$299.83K	$151.97K	$664.92K	+203%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.